The increase of healthcare expenditures faced by the public sector is one of the most discussed topics in the last century. According to researchers, this increase in spending is mainly due to the fact, that prices for pharmaceuticals and therefore expenditures for pharmaceutical products have risen over the past decade (Bardeya, Bommier and Jullien 2010: 303). Not only was this a result of an intensification in research and development (R&D) in the 1980s and 1990s through cooperation between private and public sectors (Cockburn & Henderson 2001: 30).
KeywordsAssure Defend Monopoly Daraprim
Unable to display preview. Download preview PDF.